Strensiq Market Report 2026

Strensiq Market Overview

• The Strensiq market growth in the historic period has been driven by improved recognition of hypophosphatasia, availability of orphan drug incentives • Market expansion is supported by increasing adoption in adult-onset hpp patients, expansion of rare disease treatment access • Growth Driver: Increasing Focus On Rare Disease Treatment Fuels Expansion Of Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Strensiq Market?

Strensiq refers to a prescription medication containing asfotase alfa, a targeted enzyme replacement therapy specifically designed for treating hypophosphatasia (HPP). Strensiq is utilized as a subcutaneous injection, administered several times a week, to replace the deficient enzyme in patients with hypophosphatasia, improving bone mineralization and overall skeletal health. The main types of formulations in strensiq are subcutaneous injection and single-use vials, subcutaneous injection refers to the method of administering medication, such as strensiq, directly into the layer of fat and tissue just under the skin used for various clinical indication perinatal or neonatal-onset HPP, infantile-onset HPP, childhood-onset HPP and adult-onset HPP and distributed through retail pharmacies and online pharmacies catering to different end users, pediatric and adult.

What Is The Strensiq Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption in adult-onset hpp patients, expansion of rare disease treatment access, rising investment in orphan drug pipelines, growing focus on home-based therapy administration, continued development of personalized treatment approaches. Major trends in the forecast period include increasing focus on enzyme replacement therapies, rising diagnosis rates of rare bone disorders, expansion of long-term treatment protocols, growing use of subcutaneous administration, enhanced patient monitoring and adherence programs.

Global Strensiq Market Segmentation

1) By Formulation: Subcutaneous Injection, Single-Use Vials 2) By Clinical Indication: Perinatal Or Neonatal-Onset HPP, Infantile-Onset HPP, Childhood-Onset HPP, Adult-Onset HPP 3) By Distribution Channel: Retail Pharmacies, Online Pharmacies 4) By End User: Pediatric, Adult

What Are The Drivers Of The Strensiq Market?

The increasing focus on rare disease treatment is expected to propel the growth of the strensiq market going forward. Rare disease treatment refers to medical interventions specifically designed to address conditions that affect a small percentage of the population, often involving specialized therapies or medications that may not be widely available. The increasing focus on rare disease treatment is due to precision medicine, unmet patient needs, growing regulatory incentives, and opportunities for innovation in healthcare. Strensiq, an enzyme replacement therapy, plays a pivotal role in the treatment of hypophosphatasia, a rare genetic disorder that affects bone mineralization, by replenishing the deficient alkaline phosphatase enzyme, thereby improving bone health, reducing skeletal abnormalities, and enhancing the overall quality of life for patients with this debilitating condition. For instance, in October 2024, according to a report published by the Cystic Fibrosis Trust, a UK-based non-professional organization, in the UK, the number of people registered with CF reached over 11,318 in 2023. Further, 63.7% of the UK population living with CF are over 16 years of age, and 16.7% are over 40 years of age. Therefore, the increasing focus on rare disease treatment is driving growth in the strensiq industry. The increasing personalized medicine is expected to boost the growth of the strensiq market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient. Personalized medicine is on the rise as it customizes treatments based on an individual’s genetic profile, lifestyle, and environment, enhancing therapy effectiveness and minimizing side effects. Strensiq helps personalized medicine by providing targeted enzyme replacement therapy for patients with hypophosphatasia, a rare genetic disorder, allowing for customized treatment plans that address the specific genetic mutations and varying severity of the disease in individual patients, thereby improving outcomes and quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, said the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing personalized medicine is driving growth in strensiq industry. The rise in healthcare expenditures is expected to propel the growth of the strensiq market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. Healthcare expenditures are rising as more stakeholders prioritize advanced therapies and improved patient outcomes, driving increased spending on specialized medical care. Strensiq plays a crucial role in the rise in healthcare expenditures by providing enzyme replacement therapy for hypophosphatasia, improving patient outcomes, and increasing demand for specialized treatments. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, reported that in 2023, healthcare expenditure in the UK was approximately $362.08 billion (£292 billion), reflecting a nominal increase of 5.6%. Further, healthcare spending as a share of gross domestic product (GDP) decreased slightly to 10.9% in 2023 from 11.1% in 2022. Therefore, the rise in healthcare expenditures is driving the growth of the strensiq industry.

Key Players In The Global Strensiq Market

Major companies operating in the strensiq market are AstraZeneca plc

Regional Insights

North America was the largest region in the strensiq market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Strensiq Market?

The strensiq market consists of sales of subcutaneous injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Strensiq Market Report 2026?

The strensiq market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the strensiq industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.